2. Huntington’s Disease Program
  3. HD Research Center
  4. Current Research Studies
  5. Clinical Trial: KINECT-HD2

Clinical Trial: KINECT-HD2

Kinect-HD2 is active, but not recruitingOpen-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntington’s Disease

Find this study on clinicaltrials.gov (external link) and the Huntington’s Study Group website. (external link)

SponsorHuntington Study Group & Neurocrine Biosciences, Inc.
The StudyAn open-label extension of the phase 3 KINECT-HD trial, which evaluated valbenazine (INGREZZA) for managing chorea, a hallmark symptom of Huntington's disease (HD). Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, was FDA-approved for treating HD chorea in 2023 based on results from these trials.

This extension study aims to confirm the long-term safety and effectiveness of valbenazine, including its use alongside antipsychotic medications, which are commonly prescribed to address neuropsychiatric symptoms in HD patients. Participants self-administer a once-daily dose of valbenazine, ranging from 20 mg to 80 mg, over a treatment period of up to 104 weeks. The study's design accommodates dose adjustments to suit individual needs while maintaining rigorous monitoring to assess outcomes and side effects.
PhaseIII